drugset
drugset / Trial / NCT04062981

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

NCT04062981 ↗

Phase 1 Completed 15 enrolled SK Life Science, Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

Open-label extension study from YKP509C001 to evaluate the safety and tolerability of carisbamate in subjects with Lennox-Gastaut Syndrome (LGS).

Timeline

Start
2019-05-03
Primary completion
2022-12-14
Completion
2022-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Carisbamate Small molecule — Oral

Indications

Lennox-Gastaut syndrome